These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

180 related items for PubMed ID: 33470088

  • 1. Effectiveness and safety of fully oral modified shorter treatment regimen for multidrug-resistant tuberculosis in Georgia, 2019-2020.
    Avaliani T, Sereda Y, Davtyan H, Tukvadze N, Togonidze T, Kiria N, Denisiuk O, Gozalov O, Ahmedov S, Hovhannesyan A.
    Monaldi Arch Chest Dis; 2021 Jan 14; 91(1):. PubMed ID: 33470088
    [Abstract] [Full Text] [Related]

  • 2. Effectiveness and safety of modified fully oral 9-month treatment regimens for rifampicin-resistant tuberculosis: a prospective cohort study.
    Korotych O, Achar J, Gurbanova E, Hovhannesyan A, Lomtadze N, Ciobanu A, Skrahina A, Dravniece G, Kuksa L, Rich M, Khachatryan N, Germanovych M, Kadyrov A, Terleieva I, Akhundova I, Adenov M, Durdyeva M, Kiria N, Parpieva N, Yatskevich N, Jumayev R, Nurov R, Diktanas S, Vilc V, Migliori GB, Yedilbayev A.
    Lancet Infect Dis; 2024 Oct 14; 24(10):1151-1161. PubMed ID: 38880112
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Nine months of bedaquiline, linezolid, levofloxacin, clofazimine, and cycloserine chemotherapy for rifampicin/multidrug-resistant tuberculosis: a multicenter, randomized, open-label non-inferiority trial in China.
    Song Y, Shu W, Pei Y, Du J, Wu G, Wang H, Mi F, Liu F, Ma L, Xie L, Kong Z, Wu X, Liu R, Chen H, Li H, Ge Q, Nie L, Lv Z, Huang X, Li M, Jiang M, Chen X, Cai Q, Chen W, Liu Y, Miao Y, Tang Y, Chen Y, Geng S, Zhou Q, Liu Y, Pang Y, Gao M.
    BMC Med; 2024 Sep 19; 22(1):401. PubMed ID: 39300460
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Incidence rate and time to serious adverse events among rifampicin resistant tuberculosis patients in Georgia treated with new and repurposed anti-tuberculosis drugs, 2016-2018.
    Buziashvili M, Davtyan H, Sereda Y, Denisiuk O, Gozalov O, Lomtadze N, Hovhannesyan A.
    Monaldi Arch Chest Dis; 2021 Jan 14; 91(1):. PubMed ID: 33470083
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Principles of chemotherapy for tuberculosis in national tuberculosis programmes of low- and middle-income countries.
    Chiang CY, Lin CJ.
    Indian J Tuberc; 2020 Dec 14; 67(4S):S16-S22. PubMed ID: 33308663
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].
    Saito W, Nagayama N, Miyamoto M, Hara H, Suzuki J, Masuda K, Baba M, Tamura A, Nagai H, Akagawa S, Kawabe Y, Machida K, Kurashima A, Yotsumoto H.
    Kekkaku; 2003 Oct 14; 78(10):611-7. PubMed ID: 14621568
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Treatment of Multidrug-resistant or Rifampicin-resistant Tuberculosis With an All-oral 9-month Regimen Containing Linezolid or Ethionamide in South Africa: A Retrospective Cohort Study.
    Morgan H, Ndjeka N, Hasan T, Gegia M, Mirzayev F, Nguyen LN, Schumacher S, Schlub TE, Naidoo K, Fox GJ.
    Clin Infect Dis; 2024 Jun 14; 78(6):1698-1706. PubMed ID: 38525535
    [Abstract] [Full Text] [Related]

  • 17. Cost comparison of nine-month treatment regimens with 20-month standardized care for the treatment of rifampicin-resistant/multi-drug resistant tuberculosis in Nigeria.
    Bada FO, Blok N, Okpokoro E, Dutt S, Akolo C, Dakum P, Abimiku A.
    PLoS One; 2020 Jun 14; 15(12):e0241065. PubMed ID: 33259492
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. High treatment success rate for multidrug-resistant and extensively drug-resistant tuberculosis using a bedaquiline-containing treatment regimen.
    Ndjeka N, Schnippel K, Master I, Meintjes G, Maartens G, Romero R, Padanilam X, Enwerem M, Chotoo S, Singh N, Hughes J, Variava E, Ferreira H, Te Riele J, Ismail N, Mohr E, Bantubani N, Conradie F.
    Eur Respir J; 2018 Dec 14; 52(6):. PubMed ID: 30361246
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.